Keith Leonard Net Worth
The estimated Net Worth of Keith R Leonard is at least $6.09 Million dollars as of 19 June 2019. Mr. Leonard owns over 20,000 units of Unity Biotechnology stock worth over $1,207,429 and over the last 4 years he sold UBX stock worth over $854,000. In addition, he makes $4,026,900 as Chairman of the Board and Chief Executive Officer at Unity Biotechnology.
Mr. Leonard UBX stock SEC Form 4 insider trading
Keith has made over 9 trades of the Unity Biotechnology stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of UBX stock worth $68,000 on 19 June 2019.
The largest trade he’s ever made was buying 100,000 units of Unity Biotechnology stock on 22 February 2019 worth over $250,000. On average, Keith trades about 7,312 units every 46 days since 2016. As of 19 June 2019 he still owns at least 170,782 units of Unity Biotechnology stock.
You can see the complete history of Mr. Leonard stock trades at the bottom of the page.
Keith Leonard biography
Keith R. Leonard is the Chairman of the Board, Chief Executive Officer of the Company. Before Kythera, Keith spent 13 years at Amgen, ultimately as Senior Vice President and General Manager at Amgen Europe, where he ran all commercial operations in 28 countries. Prior to that position, Keith ran Amgen’s manufacturing operations, established Amgen’s presence in rheumatology, served as Head of Information Management, and had leadership roles in sales and marketing, engineering, operations, and finance. Keith has been an Independent Director of Anacor Pharmaceuticals, Affymax, and ARYx Therapeutics. Keith holds a Master of Business Administration from The Anderson School of Management, University of California, Los Angeles, a Master of Science in Mechanical Engineering from University of California, Berkeley, a Bachelor of Arts in History from University of Maryland, College Park, and a Bachelor of Science in Engineering from University of California, Los Angeles.
What is the salary of Keith Leonard?
As the Chairman of the Board and Chief Executive Officer of Unity Biotechnology, the total compensation of Keith Leonard at Unity Biotechnology is $4,026,900. There are no executives at Unity Biotechnology getting paid more.
How old is Keith Leonard?
Keith Leonard is 57, he’s been the Chairman of the Board and Chief Executive Officer of Unity Biotechnology since 2016. There are 3 older and 10 younger executives at Unity Biotechnology. The oldest executive at Unity Biotechnology, Inc. is David Lacey, 65, who is the Independent Director.
What’s Keith Leonard’s mailing address?
Keith’s mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 3280 BAYSHORE BOULEVARD, BRISBANE, CA, 94005.
Insider trading at Unity Biotechnology
Over the last 2 years, insiders at Unity Biotechnology have traded over $0 worth of Unity Biotechnology stock. The most active insider traders include Kristina Burow, Robert Nelsen, and Paul L Berns. On average, Unity Biotechnology executives and independent directors trade stock every 126 days with the average trade being worth of $85,000. The most recent stock trade was executed by Keith R Leonard on 19 June 2019, trading 20,000 units of UBX stock currently worth $68,000.
What does Unity Biotechnology do?
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
What does Unity Biotechnology’s logo look like?
Complete history of Mr. Leonard stock trades at Intuitive Surgical, Sienna Biopharmaceuticals, and Unity Biotechnology
Unity Biotechnology executives and stock owners
Unity Biotechnology executives and other stock owners filed with the SEC include:
- Keith Leonard, Chairman of the Board, Chief Executive Officer
- Nathaniel David, President, Co-Founder, Director
- Robert Goeltz, Chief Financial Officer
- Graham Cooper, Independent Director
- Camille Samuels, Independent Director
- David Lacey, Independent Director
- Kristina Burow, Independent Director
- Paul Berns, Independent Director
- Margo Roberts, Director
- Jamie Dananberg, Chief Medical Officer
- Tamara Tompkins, General Counsel and Corporate Secretary
- Dan Marquess, Chief Scientific Officer
- Douglas Rich, Senior Vice President, Operations
- Pedro Beltran, Senior Vice President, Biology
- Robert Nelsen, Director
- Venture Partners Vii, Llcar…,
